SELLAS Life Sciences Group Sees Unusually Large Options Volume (NASDAQ:SLS)

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) was the target of unusually large options trading on Friday. Traders purchased 149,934 call options on the company. This represents an increase of 829% compared to the average daily volume of 16,138 call options.

Insider Transactions at SELLAS Life Sciences Group

In other news, Director Katherine Bach Kalin bought 63,400 shares of the business’s stock in a transaction on Wednesday, November 19th. The shares were purchased at an average price of $1.59 per share, for a total transaction of $100,806.00. Following the purchase, the director owned 104,400 shares of the company’s stock, valued at approximately $165,996. The trade was a 154.63% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 1.40% of the company’s stock.

Institutional Trading of SELLAS Life Sciences Group

Several institutional investors and hedge funds have recently added to or reduced their stakes in SLS. Bank of America Corp DE lifted its stake in SELLAS Life Sciences Group by 21.9% in the third quarter. Bank of America Corp DE now owns 42,150 shares of the company’s stock valued at $68,000 after acquiring an additional 7,571 shares during the last quarter. BNP Paribas Financial Markets raised its holdings in shares of SELLAS Life Sciences Group by 89.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 19,724 shares of the company’s stock valued at $32,000 after purchasing an additional 9,299 shares during the period. Opus Capital Group LLC raised its holdings in shares of SELLAS Life Sciences Group by 4.2% in the 3rd quarter. Opus Capital Group LLC now owns 250,000 shares of the company’s stock valued at $403,000 after purchasing an additional 10,000 shares during the period. Equitable Holdings Inc. lifted its stake in SELLAS Life Sciences Group by 58.6% in the 3rd quarter. Equitable Holdings Inc. now owns 27,060 shares of the company’s stock valued at $44,000 after purchasing an additional 10,000 shares during the last quarter. Finally, Axxcess Wealth Management LLC bought a new position in SELLAS Life Sciences Group during the third quarter worth about $26,000. 17.38% of the stock is owned by institutional investors.

SELLAS Life Sciences Group Stock Performance

SLS opened at $4.35 on Friday. The business’s 50-day simple moving average is $2.03 and its 200 day simple moving average is $1.89. SELLAS Life Sciences Group has a 52-week low of $0.85 and a 52-week high of $4.66. The firm has a market capitalization of $619.61 million, a PE ratio of -15.54 and a beta of 2.26.

SELLAS Life Sciences Group (NASDAQ:SLS) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.06) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.02. On average, research analysts forecast that SELLAS Life Sciences Group will post -0.57 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a report on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $7.00.

About SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.